DNA Chip Based Prognosis of Lung Cancer

Completed

• Conditions: Carcinoma, Non-Small-Cell Lung

• Registration Number: NCT00973427
• Lead Sponsor: Medical Prognosis Institute A/S

Brief Summary

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2009-09-08
• Study First Submitted QC: 2009-09-08
• Study First Posted: 2009-09-09
• Primary Completion: 2014-09
• Study Completion: 2014-09
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-22
• Last Update Posted: 2015-09-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 144

Inclusion Criteria

1. A histological diagnosis of primary NSCLC stage Ia
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-related survival	5 years

Secondary Outcome Measures

Name	Time	Method
Time to progression	5 years

Trial Locations

Locations (5)

University of Alabama; 🇺🇸 Birmingham, Alabama, United States

Roswell Park Cancer Institute; 🇺🇸 Buffalo, New York, United States

Aarhus University Hospital; 🇩🇰 Aarhus, Denmark

Odense University Hospital; 🇩🇰 Odense, Denmark

University of Copenhagen; 🇩🇰 Copenhagen, Denmark